×
Innoviva SG&A Expenses 2012-2026 | INVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Innoviva sg&a expenses from 2012 to 2026. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Innoviva SG&A Expenses 2012-2026 | INVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Innoviva sg&a expenses from 2012 to 2026. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Eli Lilly (LLY)
$887.6B
Johnson & Johnson (JNJ)
$574.4B
AbbVie (ABBV)
$367.7B
Roche Holding AG (RHHBY)
$318.8B
Merck (MRK)
$299.9B
Novartis AG (NVS)
$294B
Novo Nordisk (NVO)
$167.5B
Pfizer (PFE)
$153.1B
Sanofi (SNY)
$114B
Bayer (BAYRY)
$46.2B